article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

As companies undertake these steps, they increasingly rely on supply partners like Thermo Fisher who can address challenges in real time, helping maintain the highest levels of quality throughout the process without losing time or momentum.

article thumbnail

Get Prepared for New Plastic Packaging and Manufacturing Materials Requirements

PPD

In clinical research, the role of drug packaging systems cannot be overlooked. Industry guidelines require biopharmaceutical and biotechnology companies to test their pharmaceutical packaging systems, as the systems often experience prolonged and intimate contact with drug products, drug substances and intermediates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmaceutical Manufacturing And Packaging Congress 2022 Connects Pharma Leaders

The Pharma Data

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) covers the current state of the pharmaceutical manufacturing and packaging industry. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies.

article thumbnail

How to Evaluate CDMO Performance: Key Considerations and Best Practices

Drug Patent Watch

Full-Service Capabilities A full-service CDMO should provide comprehensive, end-to-end capabilities that support the entire pharmaceutical development and manufacturing process. This includes drug substance and drug product development, clinical trial logistics, product labeling, supply chain management, commercial packaging, and more.

article thumbnail

Exploring the potential of ADCs beyond oncology

Drug Target Review

They provide pharmaceutical companies with the expertise and infrastructure needed to overcome technical, logistical and regulatory hurdles, ensuring efficient development, high-quality standards and timely market entry. What role do contract development manufacturing organisations (CDMOs) play in addressing these challenges?

Therapies 120
article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

  Together with Ray Kamalika, a research bioinformatician at OMass Therapeutics, he developed Otargen , an R package offering a suite of functions to facilitate the retrieval and analysis of Open Targets Genetics data, including specialised plotting functions to help visualise the information.   Have you used Otargen?

article thumbnail

Navigating the challenges and opportunities of AI in drug development and personalised medicine

Drug Target Review

Alongside that, there is a need for some regulatory changes, or creative approaches to reviewing data packages, but regulators are well aware of that, and seem to be quite adaptive to change.” With support from pharmaceutical companies, ultimately, the answer to this question should be yes.